From Yahoo Finance · · 1m 10s
Eli Lilly Price Target Boost
Berenberg upgrades Eli Lilly to Buy with 20% upside potential.
In brief
Berenberg upgrades Eli Lilly to Buy with 20% upside potential. Berenberg raised Eli Lilly's price target to $1,400 from $1,220, predicting 20% upside based on obesity treatment growth and pipeline investments. Originally reported by Yahoo Finance.
Berenberg Upgrades Eli Lilly
Berenberg upgraded Eli Lilly from Hold to Buy and raised its price target from $1,220 to $1,400 on September 15, 2026.
Obesity Treatment Growth
Eli Lilly's Zepbound and Mounjaro lead obesity and diabetes treatments, with potential for 25% stock upside from Foundayo's diabetes approval.
Pipeline Investments
Eli Lilly committed $60 billion across 25+ business development deals this year, with multibillion-dollar sales potential in new pipeline assets.
Pricing Challenges
Eli Lilly's US price declined 3% year-over-year, with a 9% decline excluding rebates and discounts, showing pricing pressure.
Foundayo Launch
Foundayo has a slow US launch but is under regulatory review in 40+ countries, with expected approvals later this year.
Investor Sentiment
Analysts expect Eli Lilly to exceed 2026 guidance with a median price target of $1,392.50, implying 22.38% upside potential.
The bottom line
Berenberg raised Eli Lilly's price target to $1,400 from $1,220, predicting 20% upside based on obesity treatment growth and pipeline investments.
